Spinal muscular atrophy (SMA) is the leading genetic cause of death for infants. However you are impacted, we have information and resources to support your needs.
News Feed
Biogen Exercises Option with Ionis to Develop and Commercialize Investigational ASO for SMA
Biogen Inc. and Ionis Pharmaceuticals, Inc., recently announced that Biogen exercised its option to obtain from Ionis a worldwide, ...
Genentech’s Evrysdi (risdiplam) Granted FDA Priority Review for Treatment of Pre-Symptomatic Babies Under 2 Months of Age With SMA
Genentech, a member of the Roche Group, recently announced that the U.S. Food and Drug Administration (FDA) has granted priority review of ...
Cure SMA Releases Updated Drug Pipeline
We’ve recently released an update to the SMA drug pipeline. This latest version includes: 20 active programs, including three approved therapies. 10 ...
Community Spotlight
Community Spotlight: Shaakira Thomas and Family
Every August, the spinal muscular atrophy (SMA) community unites, raises awareness, and shows our pride for SMA Awareness Month. This year, ...
Community Spotlight: Dr. Arthur Burghes
On the 25th anniversary of the SMA Researcher Meeting, we would like you to learn more about Dr. Burghes and his ...
Community Spotlight: Doug McCullough
Doug McCullough was raised on a dairy farm in Pennsylvania and now resides in Central New Jersey. He is a self-described ...
Cure SMA is committed to local support.
Find resources or a treatment site in your area.
Since 1984, we’ve invested $82 million in the research that has made today’s breakthroughs possible. We advance a comprehensive research program, attacking SMA from all sides.
The Cure SMA Care Center Network
Local, evidenced-based care centers, designed to develop an evidence-based standard of care to improve the lives of all those affected by SMA.